Osteopontin is a marker for cancer aggressiveness and patient survival

• Published in: British journal of cancer Vol. 103; no. 6; pp. 861 - 869
• Main Authors: Weber, G F, Lett, G S, Haubein, N C
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.09.2010; Nature Publishing Group
• Subjects: 631/67/322; 692/53/2422; 692/699/67; 692/700/1750; Algorithms; Biological and medical sciences; Biomarkers; Biomarkers, Tumor - metabolism; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer Research; Data analysis; Datasets; Drug Resistance; Epidemiology; Head & neck cancer; Human subjects; Humans; Interlibrary loans; Keywords; Liver cancer; Lung cancer; Medical research; Medical sciences; Melanoma; Metastasis; Molecular Diagnostics; Molecular Medicine; Neoplasms - metabolism; Neoplasms - pathology; Oncology; Osteopontin - metabolism; Prostate cancer; Skin cancer; Survival Analysis; Tumors; United States > US; stage; metastasis; survival; grade; Human; Biological marker; Osteopontin; Malignancy; Metastasis; Malignant tumor; Survival; Clinical stage; Cancerology; Aggressiveness; Cancer

Background: Only a fraction of molecular cancer markers identified in the scientific literature have found clinical use. Specifically, few predictors of invasiveness are established in diagnostics. Meta-analysis is a valuable tool for biomarker validation. Here, we evaluate Osteopontin as a marker f...